In July 2024, the HEROEX-1 phase 1a/1b (NCT06521554) clinical trial was initiated to evaluate NVL-330 in pre-treated patients with advanced HER2-altered non-small cell lung cancer (NSCLC). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.